An interventional study of Catheter ablation plus medication and Medication in Atrial Fibrillation (AF), Catheter Ablation and Atrial Functional Mitral Regurgitation, sponsored by Beijing Anzhen Hospital. Recruiting at 17 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by Beijing Anzhen Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital — 25 open to participants now, 26 under way, 1 of them phase 3. Atrial Fibrillation · Beijing Anzhen Hospital.
Among the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, this one is the 22nd largest by planned enrollment of the 24 interventional ones that give a count, is one of 11 that started in 2025, is one of 21 with no phase, reaches primary completion later than 10 of the 25 other live ones, and was the 18th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →25 of the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Anzhen Hospital · Sites in China
Ages 80+
Beijing Anzhen Hospital · Sites in China
Ages 18+
Beijing Anzhen Hospital · Sites in China
Ages 18–75
Beijing Anzhen Hospital · Sites in China
Ages 18+
Beijing Anzhen Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 146 is close to the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 410 across the 24 interventional studies, 7,000 across the 12 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Anzhen Hospital is the lead sponsor of 194 studies on the registry; 103 are open to participants now.
6 of the studies in Atrial Fibrillation by Beijing Anzhen Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07411170Beijing Anzhen HospitalWearable Device-Assisted Remote Management in Atrial Fibrillation Complicated by Heart Failure: WARM-HF Trial | 2026-12 |
| NCT07541339Beijing Anzhen HospitalSafety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation | 2026-12-01 |
| NCT06791629Beijing Anzhen HospitalPulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation | 2026-12-15 |
| NCT06927908Beijing Anzhen HospitalCardiac Denervation in Aortic Arch Replacement | 2027-01-01 |
| NCT07095959Beijing Anzhen HospitalMarshall Vein Ethanol Infusion in Addition to Pulsed Electric Field Ablation Versus Pulsed Electric Field Ablation Alone for Paroxysmal Atrial Fibrillation | 2027-07-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Atrial fibrillation (AF) leads to atrial functional mitral regurgitation (MR) through mechanisms including mitral annular dilatation, systolic leaflet motion distance alteration, and contractility decrease. Compared with primary MR, atrial functional MR due to AF and other diseases tends to have a worse prognosis, with a higher risk of death and heart failure hospitalization. MR and AF co-exist and exacerbate left atrial dysfunction, further causing worse cardiac dysfunction, valvular regurgitation, and aggravating prognosis.
The best therapy for secondary MR is unclear because MR is only one component of the disease, and restoration of mitral valve competence is not curative. Catheter ablation improves symptoms and cardiac function in patients with AF, reduces risks of AF recurrence and hospitalization, as well as increases quality of life. For patients with AF combined with functional moderate-to-severe MR, previous observational studies have found that the severity of MR significantly reduced after taking catheter ablation to restore sinus rhythm. We hypothesized that catheter ablation would significantly improve the severity of MR in patients with severe atrial functional MR combined with persistent AF compared with drug therapy alone.
The ELEVATE-AF is a multi-center, open-label, parallel design, randomized controlled trial. Eligible subjects will be randomized in a 1:1 ratio to the catheter ablation combined with drug group or to the drug-alone group. A total of 146 patients with persistent atrial fibrillation and severe atrial functional mitral regurgitation (MR) (severity of moderate-to-severe [3+] or severe [4+]) will be enrolled at up to 17 investigational sites in China. The enrollment period is estimated to last approximately 18 months. The primary endpoint is the proportion of patients with residual MR of moderate [2+] or less assessed by transthoracic echocardiography at 3 months. MR severity is confirmed by the Echocardiography Core Lab according to the American Society of Cardiac Ultrasound criteria (mitral effective regurgitant orifice area [EROA)]≤20 mm2). The secondary endpoints evaluate: (i)all-cause mortality; (ii)cardiovascular hospitalization; (iii)undergoing interventional or surgical treatment of mitral valve; (iv)heart failure hospitalization or emergency room visit; (v)change in scores on the Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Questionnaire, and the 5-level EQ-5D version (EQ-5D-5L); (vi) freedom from any documented atrial arrhythmias lasting more than 30 seconds and atrial fibrillation burden. The safety endpoints include: (i)perioperative surgical complications (within 30 days after catheter ablation procedure); (ii)major bleeding (ISTH definition); (iii)stroke and systemic embolism.
As an extension of the ELEVATE-AF trial, ELEVATE-AF X study will conducted after 3-month follow-up of ELEVATE-AF. The ELEVATE-AF X study is designed as a prospective, multi-center, continued access registry study. The objective of the this study is to validate the long-term outcomes of catheter ablation procedure in patients with persistent AF and severe atrial functional MR. All patients will receive catheter ablation if the procedure is needed, and the medical therapy for ELEVATE-AF X is identical to that of ELEVATE-AF trial. Active follow-up of patients will be performed through 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients assigned to the catheter ablation group will receive AF catheter ablation and receive the same medical therapy as the control group.
Procedure: Catheter ablation plus medication · Procedure: (ELEVATE-AF X) experimental group
All patients should receive guideline-directed medical therapy, anticoagulation, and rate control with medications according to the guidelines.
Drug: Medication · Procedure: (ELEVATE-AF X) control group
All patients will receive atrial fibrillation catheter ablation. They also should receive guideline-directed medical therapy, anticoagulation, and rate control with medications according to the guidelines.
Patients will receive guideline-directed medical therapy, anticoagulation, and rate control according to the guidelines for the management of AF and heart failure.
Subsequent ablations may be considered for patients with recurrence,and the medical therapy for ELEVATE-AF X is identical to that of the ELEVATE-AF trial.
All patients could receive catheter ablation if the procedure is needed, and the medical therapy for ELEVATE-AF X is identical to that of the ELEVATE-AF trial.
The primary endpoint is the proportion of patients with residual MR of moderate [2+] or less assessed by transthoracic echocardiography at 3 months.
The primary endpoint is the proportion of patients with residual MR of moderate \[2+\] or less assessed by transthoracic echocardiography at 3 months. MR severity is confirmed by the Echocardiography Core Lab according to the American Society of Cardiac Ultrasound criteria (mitral effective regurgitant orifice area \[EROA)\]≤20 mm2).
Time frame: 3 month
all-cause mortality
Time frame: 3 month
cardiovascular hospitalization
Time frame: 3 month
undergoing interventional or surgical treatment of mitral valve
Time frame: 3 month
heart failure hospitalization or emergency room visit
Time frame: 3 month
Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) score change between baseline and 3 month
Quality of life assessed by AFEQT questionaire
Time frame: 3 month
EuroQoL 5-Dimension 5-Level (EQ-5D-5L) score change between baseline and 3 month
Quality of life assessed by EQ-5D-5L scale
Time frame: 3 month
freedom from any documented atrial arrhythmias lasting more than 30 seconds and atrial fibrillation burden
Time frame: 3 month
Change from baseline to 3 months in the 6-minute walk distance
Time frame: 3 months
(ELEVATE-AF X) the proportion of patients with residual MR of moderate [2+] or less assessed by transthoracic echocardiography
Time frame: 12 month
(ELEVATE-AF X) all-cause mortality
Time frame: 12 month
(ELEVATE-AF X) cardiovascular hospitalization
Time frame: 12 month
(ELEVATE-AF X) undergoing interventional or surgical treatment of mitral valve
Time frame: 12 month
(ELEVATE-AF X) heart failure hospitalization or emergency room visit
Time frame: 12 month
(ELEVATE-AF X) Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) score change between baseline and 12 month
Quality of life assessed by AFEQT questionaire
Time frame: 12 month
(ELEVATE-AF X) EuroQoL 5-Dimension 5-Level (EQ-5D-5L) score change between baseline and 12 month
Quality of life assessed by EQ-5D-5L scale
Time frame: 12 month
(ELEVATE-AF X) freedom from any documented atrial arrhythmias lasting more than 30 seconds and atrial fibrillation burden
Time frame: 12 month
(ELEVATE-X) Change from baseline to 12 months in the 6-minute walk distance
Time frame: 12 months
perioperative procedural complications
Time frame: 3 months
major bleeding (ISTH definition)
Time frame: 3 months
stroke and systemic embolism
Time frame: 3 months
(ELEVATE-AF X) major bleeding (ISTH definition)
Time frame: 12 month
(ELEVATE-AF X) stroke and systemic embolism
Time frame: 12 month
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Aug 2027, 27 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 27 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.